Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Pfizer/BioNTech Complete European Submission For Omicron Subvariant Adapted Vaccine

Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) have completed a submission to the European Medicines Agency (EMA) for a booster dose of an…
byVandana Singh
August 26, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0
  • Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) have completed a submission to the European Medicines Agency (EMA) for a booster dose of an Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for 12 years and older. 
  • Except for the addition to the mRNA of the Omicron BA.4/BA.5 spike protein sequence, all other vaccine components remain unchanged. 
  • Related: Boosters Are Coming For Dangerous Omicron COVID-19 Variant. Here’s Who May Be Rolling Them Out.
  • Preclinical data showed that a booster dose of omicron BA.4/BA.5-adapted bivalent vaccine generated a strong neutralizing antibody response against omicron subvariants.
  • Related: Pfizer/BioNTech’s COVID-19 Vaccine Updated Data Shows Around 76% Efficacy In Toddlers.
  • The companies have also provided safety data from clinical trials evaluating multiple variant-adapted vaccine candidates based on previous variants of concern.
  • Pfizer and BioNTech also applied with the EMA for the Omicron BA.1-adapted bivalent COVID-19 vaccine in July, which is currently under review by the Agency. The Omicron BA.1-adapted and Omicron BA.4/BA.5-adapted bivalent boosters will be available to ship shortly after respective regulatory authorizations and be available for use as early as September.
  • Price Action: PFE shares are down 1.39% at $47.24, and BNTX stock is down 2.05% at $145.52 on the last check Friday.
  • Photo via Wikimedia Commons
 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Nasdaq, S&P Futures Flatline As Key Inflation Data, More Earnings Lie In Store This Week: Analyst Flags ‘Some Caution’ On Overvaluations

By Shanthi Rexaline
February 12, 8:19 AM
U.S. stock futures once again displayed indecision on Monday, echoing recent sessions and reflecting market uncertainties. With no major earnings reports expected in the morning, attention is likely to turn to Federal Reserve officials’ speeches scheduled for the day and the New York Fed’s January consumer expectations reading.

ANET